Evaxion AS (NAS:EVAX)

Q2 2025 Evaxion A/S Earnings Call Transcript

Aug 14, 2025 / 12:30 PM GMT

Release Date Price: $2.86 (-5.92%)

Transcript

Key Points

Positve

Evaxion AS (EVAX) has a solid business development pipeline, supported by a partnership with MSD, which is on track for a potential option exercise in the second half of 2025.
The company has expanded its R&D pipeline with the addition of EVX44 and received a grant from the Gates Foundation for a polio vaccine project, enhancing its platform's application.
Evaxion AS (EVAX) has cash on hand to fund operations until mid-2026, providing financial stability and allowing the company to focus on its R&D efforts.
The company successfully converted a loan from the European Investment Bank to equity, increasing equity by $4.1 million and simplifying its balance sheet.
Evaxion AS (EVAX) is making significant progress in its oncology and infectious disease programs, with key milestones expected in the second half of 2025.

Negative

Challenging financial markets and increased regulatory uncertainty are impacting deal execution, which could affect future partnerships and funding.
The company's operating loss for Q2 2025 was $4.3 million, indicating ongoing financial challenges despite reduced spending compared to the previous year.
R&D project costs are expected to increase in the second half of the year, which could strain financial resources if not managed effectively.
The net financial expenses increased significantly to $4.7 million in Q2 2025 compared to $1.8 million in the same period last year, driven by derivative liabilities.
Despite progress, the company has not yet disclosed the two-year data for its EBX01 trial, leaving uncertainty about the trial's outcomes and potential impact on future developments.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

EVAX.OQ - Evaxion A/S
Q2 2025 Evaxion A/S Earnings Call
Aug 14, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
First and foremost, welcome to our Q2 2025 business update and financial results. I am Vicky Derene, Chief Scientific Officer and interim CEO of Eve.

And with me today, I have Thomas Smith.

Chief Financial Officer, now permanent CFO as of August 1, and Ms COO, VP of IR and communications.

Today, I will start with a short introduction, followed by an ID update, and then Thomas will present our Q2 financial results. And lastly, we are, of course, as always open for questions.

So before we begin, please note that today's presentation contains forward-looking statements based on current expectation and actual results may differ from this.

So, since last quarter, we have made significant achievements, and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.